AARD
Income statement / Annual
Last year (2024), Aardvark Therapeutics, Inc. Common Stock's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Aardvark Therapeutics, Inc. Common Stock's net income was -$20.59 M.
See Aardvark Therapeutics, Inc. Common Stock,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
| Research and Development Expenses |
$17.36 M
|
$4.48 M
|
$7.17 M
|
| General & Administrative Expenses |
$5.31 M
|
$2.17 M
|
$2.70 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$5.31 M
|
$2.17 M
|
$2.70 M
|
| Other Expenses |
$117,000.00
|
$762,000.00
|
$1.49 M
|
| Operating Expenses |
$22.79 M
|
$7.42 M
|
$11.36 M
|
| Cost And Expenses |
$22.79 M
|
$7.42 M
|
$11.36 M
|
| Interest Income |
$2.41 M
|
$1.42 M
|
$120,000.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$16,000.00
|
$97,000.00
|
$110,000.00
|
| EBITDA |
-$22.79 M |
-$7.32 M |
-$10.25 M |
| EBITDA Ratio |
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$2.20 M
|
$207,000.00
|
-$2.20 M
|
| Income Before Tax |
-$20.59 M
|
-$7.21 M
|
-$13.56 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$20.59 M
|
-$7.21 M
|
-$13.56 M
|
| Net Income Ratio |
0
|
0
|
0
|
| EPS |
-1.59 |
-0.56 |
-1.39 |
| EPS Diluted |
-1.59 |
-0.56 |
-1.39 |
| Weighted Average Shares Out |
$12.91 M
|
$12.91 M
|
$9.73 M
|
| Weighted Average Shares Out Diluted |
$12.91 M
|
$12.91 M
|
$9.73 M
|
| Link |
|
|
|
